• 1
    Kira J, Yamasaki K, Kawano Y, Kobayashi T. Acute myelitis associated with hyperIgEemia and atopic dermatitis. J Neurol Sci. 1997; 148: 199203.
  • 2
    Osoegawa M, Ochi H, Minohara M, Murai H, Umehara F, Kira J, et al. Myelitis with atopic diathesis: a nationwide survey of 79 cases in Japan. J Neurol Sci. 2003; 209: 511.
  • 3
    Isobe N, Kira J, Kawamura N, Ishizu T, Arimura K, Kawano Y. Neural damage associated with atopic diathesis: a nationwide survey in Japan. Neurology. 2009; 73: 7907.
  • 4
    Yoon JH, Joo IS, Li WU, Sohn SY. Clinical and laboratory characteristics of atopic myelitis: Korean experience. J Neurol Sci. 2009; 285: 1548.
  • 5
    Kira J. Multiple sclerosis in the Japansese population. Lancet Neurol. 2003; 2: 11727.
  • 6
    Tanaka M, Matsushita T, Tateishi T, Ochi H, Kawano Y, Kira J, et al. Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology. 2008; 71: 97481.
  • 7
    Osoegawa M, Ochi H, Kikuchi H, Shirabe S, Nagashima T, Kira J, et al. Eosinophilic myelitis associated with atopic diathesis: a combined neuroimaging and histopathological study. Acta Neuropathol. 2003; 105: 28995.
  • 8
    Osoegawa M, Ochi H, Yamada T, Horiuchi I, Murai H, Kira J, et al. High incidence of subclinical peripheral neurpathy in myelitis with hyperIgEaemia and mite antigen-specific IgE (atopic myelitis): an electrophyiological study. Intern Med. 2002; 41: 68491.
  • 9
    Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005; 58: 8406.
  • 10
    Matsuoka T, Matsushita T, Kawano Y, Osoegawa M, Ochi H, Kira J, et al. Heterogeneity of aquaporin-4 autoimmunity and spina cord lesions in multiple sclerosis in Japanese. Brain. 2007; 130: 120623.
  • 11
    Matsushita T, Matsuoka T, Isobe N, Kawano Y, Minohara M, Kira J, et al. Association of the HLA-DPB1*0501 allele with anti-aquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders. Tissue Antigens. 2009; 73: 1716.
  • 12
    Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33: 144452.
  • 13
    Watanabe A, Matsushita T, Doi H, Matsuoka T, Shigeto H, Kira J, et al. Multimodality-evoked potential study of anti-aquaporin-4 antibody-positive and –negative multiple sclerosis patients. J Neurol Sci. 2009; 281: 3440.
  • 14
    Matsushita T, Isobe N, Matsuoka T, Shi N, Kawano Y, Wu XM, et al. Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese. Mult Scler. 2009; 15: 83447.
  • 15
    Kira J. Recent advance of multiple sclerosis research in Japan. Clin Neurol. 2009; 49: 54959.
  • 16
    Constantinescu CS, Thomas M, Zaman AG. Atopic optic neuritis. Ocul Immunol Inflamm. 2006; 14: 1257.
  • 17
    Pou SA, Roquer GJ, Perich AX. Acute posterior cord lesions in multiple sclerosis. An MRI study of the clinical course in 20 cases. Rev Neurol. 2000; 156: 112635.
  • 18
    Kira J. Neuromyelitis optica and opticospianal multiple sclerosis: mechanisisms and pathogenesis. Pathophysiology. 2011; 18: 6979.
  • 19
    Qin Y, Zhang DQ, Prat A, Pouly S, Antel J. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients. J Neuroimmunol. 2000; 108: 2016.
  • 20
    Martin-Saavedra FM, Gonzalez-Garcia C, Bravo B, Ballester S. Beta interferon restricts the inflammatory potential of CD4+ cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells. Mol Immunol. 2008; 45: 400819.